Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression

Gynecologic Oncology

Volumn 92, Issue 1, 2004, Pages 80-88

  Murthi, Padma ^a   Barker, Gillian ^b   Nowell, Cameron J ^a   Rice, Gregory E ^a,b   Baker, Mark S ^c   Kalionis, Bill ^d   Quinn, Michael A ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Gynecological Cancer Research Centre   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

Angiostatin; Metalloproteinases; Ovarian cancer; Plasminogen; Proteases; Zymography

Indexed keywords

ANGIOSTATIN; GELATINASE A; GELATINASE B; PLASMINOGEN; PLASMINOGEN[GLUTAMIC ACID]; PLASMINOGEN[LYSINE]; PROTEINASE; TISSUE EXTRACT; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; BIOSYNTHESIS; CANCER GRADING; CANCER GROWTH; CONTROLLED STUDY; CYSTADENOCARCINOMA; DENSITOMETRY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME SYNTHESIS; ENZYMOLOGY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; METABOLISM; MOLECULAR WEIGHT; OVARY CARCINOMA; OVARY TUMOR; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; URINALYSIS; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 0742307276     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.09.016     Document Type: Article

References (37)

1. Hoskins W.J. Prospective on ovarian cancer. J. Cell. Biochem., Suppl. 23:1995;189-199.
2. Andreasen P.A., Kjoller L., Christensen L., Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer. 72:1997;1-22.
3. Mignatti P., Rifkin D. Biology and biochemistry of proteases in tumor invasion. Physiol. Rev. 73:1993;161-195.
4. Dano K., Andreasen P.A., Grondahl-Hansen J., Kristensen P., Nielsen L.S., Skriver L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res. 44:1985;139-266.
5. Ossowski L. Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell. 52(3):1998;321-328.
6. Cao Y. Endogenous angiogenesis inhibitors: angiostatin, endostatin, and other proteolytic fragments. Prog. Mol. Subcell. Biol. 20:1998;161-176.
7. Carmeliet P., Moons L., Dewerchin M., Mackman N., Luther T., Breier G.et al. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann. N.Y. Acad. Sci. 811:1997;191-206. [Review].
8. Marshall J.M., Brown A.J., Ponting C.P. Conformational studies of human plasminogen and plasminogen fragments: evidence for a novel third conformation of plasminogen. Biochemistry. 33(12):1994;3599-3606.
9. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79(2):1994;315-328.
10. O'Reilly M.S., Holmgren L., Chen C., Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2(6):1996;689-692.
11. Fishman D.A., Bafetti L.M., Banionis S., Keam A.S., Chilukuri K., Stack M.S. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer. 80(8):1997;1457-1463.
12. Davies B., Waxman J., Wasan H., Abel P., Williams G., Krausz T.et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 15(53(22)):1993;5365-5369.
13. Tecimer C., Doering D.L., Goldsmith L.J., Meyer J.S., Abdulhay G., Wittliff J.L. Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. Int. J. Gynecol. Cancer. 10(5):2000;372-381.
14. Schmalfeldt B., Prechtel D., Harting K., Spathe K., Rutke S., Konik E.et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin. Cancer Res. 7(8):2001;2396-2404.
15. Heussen C., Dowdle E.B. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal. Biochem. 102(1):1980;196-202.
16. Lim M., Elfman F., Dohrman A., Cunha G., Basbaum C. Upregulation of the 72-kDa-type IV collagenase in epithelial and stromal cells during rat tracheal gland morphogenesis. Dev. Biol. 171(2):1995;521-530.
17. Boss E.A., Massager L.F., Thomas C.M., Geurts-Moespot A., van Saik J.H., Boonstra H.et al. Clinical value of components of the plasminogen activation system in ovarian cyst fluid. Anticancer Res. 22(1A):2002;275-282.
18. Kiziridou A.D., Toliou T., Stefanou D., Agnantis N. u-PA expression in benign, borderline and malignant ovarian tumors. Anticancer Res. 22(2A):2002;985-990.
19. O'Reilly M.S., Wiederschain D., Stetler-Stevenson W.G., Folkman J., Moses M.A. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J. Biol. Chem. 274(41):1999;29568-29571.
20. Gately S., Twardowski P., Stack M.S., Patrick M., Boggio L., Cundiff D.L.et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res. 56(21):1996;4887-4890.
21. Dong Z., Kumar R., Yang X., Fidler I.J. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell. 88(6):1997;801-810.
22. Dong Z., Yoneda J., Kumar R., Fidler I.J. Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 188(4):1998;755-763.
23. Gately S., Twardowski P., Stack M.S., Cundiff D.L., Grella D., Castellino F.J.et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Natl. Acad. Sci. U. S. A. 94(20):1997;10868-10872.
24. Stathakis P., Fitzgerald M., Matthias L.J., Chesterman C.N., Hogg P.J. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells. J. Biol. Chem. 272(33):1997;20641-20645.
25. Stathakis P., Lay A.J., Fitzgerald M., Schlieker C., Matthias L.J., Hogg P.J. Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin. J. Biol. Chem. 274(13):1999;8910-8916.
26. Patterson B.C., Sang Q.A. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J. Biol. Chem. 272(46):1997;28823-28825.
27. Mauceri H.J., Hanna N.N., Beckett M.A., Gorski D.H., Staba M.J., Stellato K.A.et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature. 394(6690):1998;287-291.
28. Richardson M., Gunawan J., Hatton M.W., Seidlitz E., Hirte H.W., Singh G. Malignant ascites (MAF), including ovarian cancer-associated MAF, contains angiostatin and other factors, which inhibit angiogenesis. Gynecol Oncol. 86(3):2002;279-287.
29. Westerlund A., Apaja-Sarkkinen M., Hoyhtya M., Puistola U., Turpeenniemi-Hujanen T. Gelatinase A-immunoreactive protein in ovarian lesions-prognostic value in epithelial ovarian cancer. Gynecol. Oncol. 75(1):1999;91-98.
30. Lengyel E., Schmalfeldt B., Konik E., Spathe K., Harting K., Fenn A.et al. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol. Oncol. 82(2):2001;291-298.
31. Himelstein B.P., Canete-Soler R., Bernhard E.J., Dilks D.W., Muschel R.J. Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis. 14(1-6):1995;246-258. [Review].
32. Ellerbroek S.M., Hudson L.G., Stack M.S. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int. J. Cancer. 78(3):1998;331-337.
33. Bernhard E.J., Gruber S.B., Muschel R.J. Direct evidence-linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc. Natl. Acad. Sci. U. S. A. 91(10):1994;4293-4297.
34. Furuya M., Ishikura H., Ogawa Y., Kawarada Y., Shibata M., Fujimoto S.et al. Analyses of matrix metalloproteinases and their inhibitors in cyst fluid of serous ovarian tumors. Pathobiology. 68(6):2000;239-244.
35. Behrens P., Rothe M., Florin A., Wellmann A., Wernert N. Invasive properties of serous epithelial ovarian tumors are related to Ets1, MMP-1 and MMP-9 expression. Int. J. Mol. Med. 8(2):2001;149-154.
36. Shushan A., Paltiel O., Schenker J.G. Induction of ovulation and borderline ovarian cancer - The hormonal connection? Review. Eur. J. Obstet., Gynecol., Reprod. Biol. 85(1):1999;71-74.
37. Stack M.S., Ellerbroek S.M., Fishman D.A. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. Int. J. Oncol. (3):1998;569-576. [Review].